aid: pulmocide
name: Pulmocide
description: >-
  Pulmocide Ltd. is a privately held, clinical-stage biopharmaceutical company headquartered at 44
  Southampton Buildings in London, United Kingdom, with a US entity (Pulmocide Inc.) in Boston,
  Massachusetts. It develops novel inhaled medicines for pulmonary aspergillosis and other
  difficult-to-treat respiratory diseases, delivering drug directly to the site of infection in the
  lung to achieve high local exposure with low systemic exposure. Its lead asset is opelconazole
  (formerly PC945), an inhaled triazole antifungal active against Aspergillus that has received US
  FDA Orphan Drug, Fast Track and Qualified Infectious Disease Product designations; the company
  reported Phase 2 OPERA-S safety results in 2024 and announced termination of the Phase 3 OPERA-T
  study in 2025. Pulmocide is a drug developer, not a software or platform company: it publishes no
  developer program, no public API, no SDKs and no machine-readable API contract of any kind. This
  profile therefore records identity, corporate web properties and probed absence rather than API
  artifacts.
url: https://raw.githubusercontent.com/api-evangelist/pulmocide/refs/heads/main/apis.yml
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
image: https://pulmocide.com/wp-content/uploads/2023/08/PULM_OG_Facebook.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Respiratory
- Antifungal
- Drug Development
- Healthcare
- United Kingdom
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: LLMsTxt
  url: llms/pulmocide-llms.txt
- type: DomainSecurity
  url: security/pulmocide-domain-security.yml
- type: Website
  url: https://pulmocide.com/
- type: About
  url: https://pulmocide.com/about-us/
- type: Contact
  url: https://pulmocide.com/contact/
- type: News
  url: https://pulmocide.com/in-the-news/
- type: BlogRSS
  url: https://pulmocide.com/feed/
- type: Investors
  url: https://pulmocide.com/investors-and-partners/
- type: PrivacyPolicy
  url: https://pulmocide.com/privacy-notice/
- type: CookiePolicy
  url: https://pulmocide.com/cookie-policy/
- type: Accessibility
  url: https://pulmocide.com/accessibility/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Pulmocide Ltd. is a clinical-stage biopharmaceutical company whose product is an inhaled
    antifungal drug (opelconazole), not software; its only web property is a twelve-page WordPress
    marketing site with no developer section, and every contract-discovery path on pulmocide.com
    (/openapi.json, /graphql, /llms.txt, every /.well-known/*) returned 404 while the site's stock
    WordPress /wp-json/ discovery root is default CMS plumbing rather than an API the company ships.
  evidence:
  - url: https://pulmocide.com/openapi.json
    status: 404
  - url: https://pulmocide.com/graphql
    status: 404
  - url: https://pulmocide.com/llms.txt
    status: 404
  - url: https://pulmocide.com/.well-known/agent-card.json
    status: 404
  - url: https://pulmocide.com/wp-json/
    status: 200
  - url: https://github.com/pulmocide
    status: 404
  checked: '2026-08-26'